CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Status:
Not yet recruiting
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
This study will look at how effective the study drug (tepotinib) is at stopping the growth
and spread of lung cancer with central nervous system metastasis. In some patients, who have
developed resistance to their tyrosine kinase inhibitors (TKIs), this study will look at how
effective tepotinib is in combination with TKIs. This study will also measure a number of
other things including safety of the study drug and the side effects, how body processes the
study drug, or how the study drug affects your quality of life.